

Daniel Golparian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2724305/publications.pdf>

Version: 2024-02-01

93
papers

4,961
citations

109264

35
h-index

102432

66
g-index

98
all docs

98
docs citations

98
times ranked

2636
citing authors

#	ARTICLE	IF	CITATIONS
1	Gentamicin Susceptibility in <i>Neisseria gonorrhoeae</i> and Treatment Outcomes for Urogenital Gonorrhea After 25 Years of Sustained Gentamicin Use in Malawi. <i>Sexually Transmitted Diseases</i> , 2022, 49, 251-256.	0.8	9
2	Antimicrobial resistance prediction in <i>Neisseria gonorrhoeae</i> : current status and future prospects. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 29-48.	1.5	18
3	Pharmacodynamic Evaluation of Zoliflodacin Treatment of <i>Neisseria gonorrhoeae</i> Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection Model. <i>Frontiers in Pharmacology</i> , 2022, 13, 874176.	1.6	15
4	A Single Amino Acid Substitution in Elongation Factor G Can Confer Low-Level Gentamicin Resistance in <i>Neisseria gonorrhoeae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0025122.	1.4	4
5	Europe-wide expansion and eradication of multidrug-resistant <i>Neisseria gonorrhoeae</i> lineages: a genomic surveillance study. <i>Lancet Microbe</i> , The, 2022, 3, e452-e463.	3.4	44
6	Genomic surveillance and antimicrobial resistance in <i>Neisseria gonorrhoeae</i> isolates in Bangkok, Thailand in 2018. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	1.3	11
7	Extensively drug-resistant (XDR) <i>Neisseria gonorrhoeae</i> causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022. <i>Eurosurveillance</i> , 2022, 27, .	3.9	35
8	Evaluation of the SpeedXResistancePlus®GC and SpeedX GC 23S 2611 (beta) molecular assays for prediction of antimicrobial resistance/susceptibility to ciprofloxacin and azithromycin in <i>Neisseria gonorrhoeae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 84-90.	1.3	10
9	<i>Neisseria gonorrhoeae</i> Sequence Typing for Antimicrobial Resistance (NG-STAR) clonal complexes are consistent with genomic phylogeny and provide simple nomenclature, rapid visualization and antimicrobial resistance (AMR) lineage predictions. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 940-944.	1.3	22
10	High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical <i>Neisseria gonorrhoeae</i> isolates from 25 European countries, 2018. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1221-1228.	1.3	31
11	A community-driven resource for genomic epidemiology and antimicrobial resistance prediction of <i>Neisseria gonorrhoeae</i> at Pathogenwatch. <i>Genome Medicine</i> , 2021, 13, 61.	3.6	63
12	Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against <i>Neisseria gonorrhoeae</i> in a Dynamic Hollow Fiber Infection Model. <i>Frontiers in Pharmacology</i> , 2021, 12, 682135.	1.6	23
13	Antimicrobial resistance and molecular epidemiological typing of <i>Neisseria gonorrhoeae</i> isolates from Kyrgyzstan in Central Asia, 2012 and 2017. <i>BMC Infectious Diseases</i> , 2021, 21, 559.	1.3	4
14	Antimicrobial resistance in <i>Neisseria gonorrhoeae</i> isolates and gonorrhoea treatment in the Republic of Belarus, Eastern Europe, 2009–2019. <i>BMC Infectious Diseases</i> , 2021, 21, 520.	1.3	8
15	Lack of diagnostic-escape mutants of group B streptococcus in Slovenia. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1054-1055.	2.8	3
16	Genomic Epidemiology of Azithromycin-Nonsusceptible <i>Neisseria gonorrhoeae</i> , Argentina, 2005–2019. <i>Emerging Infectious Diseases</i> , 2021, 27, 2369-2378.	2.0	7
17	First National Genomic Epidemiological Study of <i>Neisseria gonorrhoeae</i> Strains Spreading Across Sweden in 2016. <i>Frontiers in Microbiology</i> , 2021, 12, 820998.	1.5	8
18	Genomic epidemiology of <i>Neisseria gonorrhoeae</i> elucidating the gonococcal antimicrobial resistance and lineages/sublineages across Brazil, 2015–16. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3163-3172.	1.3	29

#	ARTICLE	IF	CITATIONS
19	Adaptation to the cervical environment is associated with increased antibiotic susceptibility in <i>Neisseria gonorrhoeae</i> . <i>Nature Communications</i> , 2020, 11, 4126.	5.8	51
20	Sensitivity, specificity, inclusivity and exclusivity of the updated Aptima Combo 2 assay, which provides detection coverage of the new diagnostic-escape <i>Chlamydia trachomatis</i> variants. <i>BMC Infectious Diseases</i> , 2020, 20, 419.	1.3	10
21	Prevalence of <i>Mycoplasma genitalium</i> and Antibiotic Resistance-Associated Mutations in Patients at a Sexually Transmitted Infection Clinic in Iceland, and Comparison of the S-DiaMGTV and Aptima <i>Mycoplasma genitalium</i> Assays for Diagnosis. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	8
22	Genomic evolution of <i>Neisseria gonorrhoeae</i> since the preantibiotic era (1928–2013): antimicrobial use/misuse selects for resistance and drives evolution. <i>BMC Genomics</i> , 2020, 21, 116.	1.2	57
23	Genomic analysis and antimicrobial resistance of <i>Neisseria gonorrhoeae</i> isolates from Vietnam in 2011 and 2015–16. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1432-1438.	1.3	28
24	Prevalence and risk factors associated with <i>Chlamydia trachomatis</i> , <i>Neisseria gonorrhoeae</i> , and <i>Mycoplasma genitalium</i> among women in Pelotas, Southern Brazil. <i>International Journal of STD and AIDS</i> , 2020, 31, 432-439.	0.5	9
25	Genomic epidemiology and antimicrobial resistance determinants of <i>Neisseria gonorrhoeae</i> isolates from Ukraine, 2013–2018. <i>Apmis</i> , 2020, 128, 465-475.	0.9	13
26	Genomic and phenotypic characterisation of invasive neonatal and colonising group B <i>Streptococcus</i> isolates from Slovenia, 2001–2018. <i>BMC Infectious Diseases</i> , 2020, 20, 958.	1.3	9
27	The impact of antimicrobials on gonococcal evolution. <i>Nature Microbiology</i> , 2019, 4, 1941-1950.	5.9	91
28	Genetic variation regulates the activation and specificity of Restriction-Modification systems in <i>Neisseria gonorrhoeae</i> . <i>Scientific Reports</i> , 2019, 9, 14685.	1.6	14
29	In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for <i>Neisseria gonorrhoeae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3521-3529.	1.3	24
30	Antimicrobial Resistance in <i>Neisseria gonorrhoeae</i> and Treatment of Gonorrhoea. <i>Methods in Molecular Biology</i> , 2019, 1997, 37-58.	0.4	71
31	Prediction of Minimum Inhibitory Concentrations of Antimicrobials for <i>Neisseria gonorrhoeae</i> Using Whole-Genome Sequencing. <i>Methods in Molecular Biology</i> , 2019, 1997, 59-76.	0.4	8
32	High prevalence of <i>Chlamydia trachomatis</i> , <i>Neisseria gonorrhoeae</i> and particularly <i>Trichomonas vaginalis</i> diagnosed using US FDA-approved Aptima molecular tests and evaluation of conventional routine diagnostic tests in Ternopil, Ukraine. <i>Apmis</i> , 2019, 127, 627-634.	0.9	22
33	Now Is the Time to Implement Whole Genome Sequencing in the Global Antimicrobial Resistance Surveillance for <i>Neisseria gonorrhoeae</i> ?. <i>EClinicalMedicine</i> , 2019, 7, 11-12.	3.2	1
34	Antimicrobial susceptibility of <i>Neisseria gonorrhoeae</i> isolates and treatment of gonorrhoea patients in Ternopil and Dnipropetrovsk regions of Ukraine, 2013–2018. <i>Apmis</i> , 2019, 127, 503-509.	0.9	24
35	Genome-based epidemiology and antimicrobial resistance determinants of <i>Neisseria gonorrhoeae</i> isolates with decreased susceptibility and resistance to extended-spectrum cephalosporins in Argentina in 2011–16. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1551-1559.	1.3	33
36	P637... <i>Neisseria gonorrhoeae</i> genomic diversity in high risk groups in Switzerland. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
37	O06.2â€¦In vitro combination testing and selection of resistance to zoliflodacin combined with six antimicrobials for <i>N. gonorrhoeae</i> . , 2019, , .		0
38	Aptima <i>Trichomonas vaginalis</i> assay elucidates significant underdiagnosis of trichomoniasis among women in Brazil according to an observational study. Sexually Transmitted Infections, 2019, 95, 129-132.	0.8	12
39	Macrolide and fluoroquinolone resistance in <i>Mycoplasma genitalium</i> in two Swedish counties, 2011â€“2015. Apmis, 2018, 126, 123-127.	0.9	20
40	Clinical and analytical evaluation of the new Aptima <i>Mycoplasma genitalium</i> assay, with data on <i>M. genitalium</i> prevalence and antimicrobial resistance in <i>M. genitalium</i> in Denmark, Norway and Sweden in 2016. Clinical Microbiology and Infection, 2018, 24, 533-539.	2.8	74
41	In vitro activity and timeâ€kill curve analysis of sitafloxacin against a global panel of antimicrobialâ€resistant and multidrugâ€resistant <i>Neisseria gonorrhoeae</i> isolates. Apmis, 2018, 126, 29-37.	0.9	16
42	Gonorrhoea treatment failure caused by a <i>Neisseria gonorrhoeae</i> strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Eurosurveillance, 2018, 23, .	3.9	255
43	WHO laboratory validation of Xpert ^Â CT/NG and Xpert ^Â TV on the GeneXpert system verifies high performances. Apmis, 2018, 126, 907-912.	0.9	45
44	Antimicrobial resistance prediction and phylogenetic analysis of <i>Neisseria gonorrhoeae</i> isolates using the Oxford Nanopore MinION sequencer. Scientific Reports, 2018, 8, 17596.	1.6	59
45	Public health surveillance of multidrug-resistant clones of <i>Neisseria gonorrhoeae</i> in Europe: a genomic survey. Lancet Infectious Diseases, The, 2018, 18, 758-768.	4.6	164
46	In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR <i>Neisseria gonorrhoeae</i> . Journal of Antimicrobial Chemotherapy, 2018, 73, 2072-2077.	1.3	50
47	Multidrug-resistant <i>Neisseria gonorrhoeae</i> isolate, belonging to the internationally spreading Japanese FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, Ireland, August 2018. Eurosurveillance, 2018, 23, .	3.9	80
48	<i>Trichomonas vaginalis</i> is very rare among women with vaginal discharge in Podlaskie province, Poland. Apmis, 2017, 125, 840-843.	0.9	6
49	In Vitro Activity of the Novel Pleuromutilin Lefamulin (BC-3781) and Effect of Efflux Pump Inactivation on Multidrug-Resistant and Extensively Drug-Resistant <i>Neisseria gonorrhoeae</i> . Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	48
50	Recent advances in the development and use of molecular tests to predict antimicrobial resistance in <i>Neisseria gonorrhoeae</i> . Expert Review of Molecular Diagnostics, 2017, 17, 845-859.	1.5	61
51	Prevalence of macrolide and fluoroquinolone resistance-mediating mutations in <i>Mycoplasma genitalium</i> in five cities in Russia and Estonia. PLoS ONE, 2017, 12, e0175763.	1.1	39
52	LB1.69â€¦Clinical and analytical evaluation of the new aptimamycoplasma genitalium assay on the panther instrument (HOLOGIC), <i>m. genitalium</i> prevalence, and antimicrobial resistance in <i>m. genitalium</i> in sweden, denmark and norway in 2016. , 2017, , .		0
53	<i>Trichomonas vaginalis</i> is Rare Among Women in Iceland. Acta Dermato-Venereologica, 2017, 97, 1258-1260.	0.6	5
54	WGS analysis and molecular resistance mechanisms of azithromycin-resistant (MIC >2) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 Td (Chemotherapy, 2016, 71, 3109-3116.	1.3	81

#	ARTICLE	IF	CITATIONS
55	The novel 2016 WHO <i>Neisseria gonorrhoeae</i> reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3096-3108.	1.3	246
56	Efflux Pumps in <i>Neisseria gonorrhoeae</i> : Contributions to Antimicrobial Resistance and Virulence. , 2016, , 439-469.		10
57	Failure of Dual Antimicrobial Therapy in Treatment of Gonorrhoea. <i>New England Journal of Medicine</i> , 2016, 374, 2504-2506.	13.9	283
58	Analytical specificity and sensitivity of the novel dual-target GeneProof <i>Neisseria gonorrhoeae</i> PCR kit for detection of <i>N. gonorrhoeae</i> . <i>Apmis</i> , 2015, 123, 955-958.	0.9	3
59	Genetic Resistance Determinants, In Vitro Time-Kill Curve Analysis and Pharmacodynamic Functions for the Novel Topoisomerase II Inhibitor ETX0914 (AZD0914) in <i>Neisseria gonorrhoeae</i> . <i>Frontiers in Microbiology</i> , 2015, 6, 1377.	1.5	44
60	In vitro activities of the novel bicyclic modithromycin (EDP-420, EP-013420, S-013420) and EDP-322 against MDR clinical <i>Neisseria gonorrhoeae</i> isolates and international reference strains. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 173-177.	1.3	17
61	Will Genome Analysis Elucidate Evolution, Global Transmission and Virulence of <i>Neisseria Meningitidis</i> Lineages?. <i>EBioMedicine</i> , 2015, 2, 186-187.	2.7	3
62	<i>Trichomonas vaginalis</i> Infections are Rare Among Young Patients Attending an STI Clinic in Sweden. <i>Acta Dermato-Venereologica</i> , 2015, 95, 343-344.	0.6	9
63	Antimicrobial susceptibility/resistance and NG-MAST characterisation of <i>Neisseria gonorrhoeae</i> in Belarus, Eastern Europe, 2010-2013. <i>BMC Infectious Diseases</i> , 2015, 15, 29.	1.3	29
64	Evaluation of the New BD Max GC Real-Time PCR Assay, Analytically and Clinically as a Supplementary Test for the BD ProbeTec GC Qx Amplified DNA Assay, for Molecular Detection of <i>Neisseria gonorrhoeae</i> . <i>Journal of Clinical Microbiology</i> , 2015, 53, 3935-3937.	1.8	7
65	Evaluation of the new AmpliSens multiplex real-time PCR assay for simultaneous detection of <i>Neisseria gonorrhoeae</i> , <i>Chlamydia trachomatis</i> , <i>Mycoplasma genitalium</i> , and <i>Trichomonas vaginalis</i> . <i>Apmis</i> , 2015, 123, 879-886.	0.9	46
66	First Three <i>Neisseria gonorrhoeae</i> Isolates with High-Level Resistance to Azithromycin in Sweden: a Threat to Currently Available Dual-Antimicrobial Regimens for Treatment of Gonorrhoea?. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 624-625.	1.4	56
67	Phenotypic and molecular characterization of <i>Neisseria gonorrhoeae</i> isolates from Slovenia, 2006-12: rise and fall of the multidrug-resistant NG-MAST genogroup 1407 clone?. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1517-1525.	1.3	33
68	High In Vitro Activity of the Novel Spiropyrimidinetrione AZD0914, a DNA Gyrase Inhibitor, against Multidrug-Resistant <i>Neisseria gonorrhoeae</i> Isolates Suggests a New Effective Option for Oral Treatment of Gonorrhoea. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5585-5588.	1.4	62
69	Antimicrobial susceptibility/resistance and genetic characteristics of <i>Neisseria gonorrhoeae</i> isolates from Poland, 2010-2012. <i>BMC Infectious Diseases</i> , 2014, 14, 65.	1.3	18
70	Importance of Multidrug Efflux Pumps in the Antimicrobial Resistance Property of Clinical Multidrug-Resistant Isolates of <i>Neisseria gonorrhoeae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3556-3559.	1.4	96
71	Verified clinical failure with cefotaxime 1g for treatment of gonorrhoea in the Netherlands: a case report. <i>Sexually Transmitted Infections</i> , 2014, 90, 513-514.	0.8	14
72	Characterisation of bla _{TEM} genes and types of β -lactamase plasmids in <i>Neisseria gonorrhoeae</i> – the prevalent and conserved bla _{TEM} -135 has not recently evolved and existed in the Toronto plasmid from the origin. <i>BMC Infectious Diseases</i> , 2014, 14, 454.	1.3	57

#	ARTICLE	IF	CITATIONS
73	High in vitro activity of a novel dual bacterial topoisomerase inhibitor of the ATPase activities of GyrB and ParE (VT12-008911) against <i>Neisseria gonorrhoeae</i> isolates with various high-level antimicrobial resistance and multidrug resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1866-1872.	1.3	19
74	Challenges with gonorrhea in the era of multi-drug and extensively drug resistance “are we on the right track?”. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 653-656.	2.0	30
75	Antimicrobial susceptibility and genetic characteristics of <i>Neisseria gonorrhoeae</i> isolates from Vietnam, 2011. <i>BMC Infectious Diseases</i> , 2013, 13, 40.	1.3	54
76	Antimicrobial susceptibility and genetic characteristics of <i>Neisseria gonorrhoeae</i> isolates from India, Pakistan and Bhutan in 2007-2011. <i>BMC Infectious Diseases</i> , 2013, 13, 35.	1.3	24
77	<i>Neisseria gonorrhoeae</i> Strain with High-Level Resistance to Spectinomycin Due to a Novel Resistance Mechanism (Mutated Ribosomal Protein S5) Verified in Norway. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1057-1061.	1.4	74
78	Whole-genome sequences of <i>Chlamydia trachomatis</i> directly from clinical samples without culture. <i>Genome Research</i> , 2013, 23, 855-866.	2.4	115
79	Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant <i>Neisseria gonorrhoeae</i> infection in South Africa and association with cefixime treatment failure. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1267-1270.	1.3	108
80	Evolution of <i>Neisseria gonorrhoeae</i> is a continuing challenge for molecular detection of gonorrhoea: false negative gonococcal <i>porA</i> mutants are spreading internationally. <i>Sexually Transmitted Infections</i> , 2013, 89, 197-201.	0.8	33
81	Analytical Evaluation of GeneXpert CT/NG, the First Genetic Point-of-Care Assay for Simultaneous Detection of <i>Neisseria gonorrhoeae</i> and <i>Chlamydia trachomatis</i> . <i>Journal of Clinical Microbiology</i> , 2013, 51, 1945-1947.	1.8	70
82	Analytical Specificity and Sensitivity of the APTIMA Combo 2 and APTIMA GC Assays for Detection of Commensal <i>Neisseria</i> Species and <i>Neisseria gonorrhoeae</i> on the Gen-Probe Panther Instrument. <i>Sexually Transmitted Diseases</i> , 2013, 40, 175-178.	0.8	17
83	Evaluation of <i>Neisseria gonorrhoeae</i> Multiple-Locus Variable-Number Tandem-Repeat Analysis, <i>N. gonorrhoeae</i> Multiantigen Sequence Typing, and Full-Length <i>porB</i> Gene Sequence Analysis for Molecular Epidemiological Typing. <i>Journal of Clinical Microbiology</i> , 2012, 50, 180-183.	1.8	9
84	In Vitro Activity of Ertapenem versus Ceftriaxone against <i>Neisseria gonorrhoeae</i> Isolates with Highly Diverse Ceftriaxone MIC Values and Effects of Ceftriaxone Resistance Determinants: Ertapenem for Treatment of Gonorrhea?. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3603-3609.	1.4	63
85	In Vitro Activity of the New Fluoroketolide Solithromycin (CEM-101) against a Large Collection of Clinical <i>Neisseria gonorrhoeae</i> Isolates and International Reference Strains, Including Those with High-Level Antimicrobial Resistance: Potential Treatment Option for Gonorrhea?. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2739-2742.	1.4	90
86	Clonally Related <i>Neisseria gonorrhoeae</i> Isolates with Decreased Susceptibility to the Extended-Spectrum Cephalosporin Cefotaxime in Amsterdam, the Netherlands. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1516-1522.	1.4	27
87	Reply to “Management of Pharyngeal Gonorrhea Is Crucial To Prevent the Emergence and Spread of Antibiotic-Resistant <i>Neisseria gonorrhoeae</i> ”. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4041-4042.	1.4	3
88	High-Level Cefixime- and Ceftriaxone-Resistant <i>Neisseria gonorrhoeae</i> in France: Novel <i>penA</i> Mosaic Allele in a Successful International Clone Causes Treatment Failure. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1273-1280.	1.4	546
89	Genome Sequencing of a <i>Neisseria gonorrhoeae</i> Isolate of a Successful International Clone with Decreased Susceptibility and Resistance to Extended-Spectrum Cephalosporins. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5633-5641.	1.4	31
90	Is <i>Neisseria gonorrhoeae</i> Initiating a Future Era of Untreatable Gonorrhea?: Detailed Characterization of the First Strain with High-Level Resistance to Ceftriaxone. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3538-3545.	1.4	600

#	ARTICLE	IF	CITATIONS
91	Antimicrobial susceptibility/resistance and molecular epidemiological characteristics of <i>Neisseria gonorrhoeae</i> in 2009 in Belarus. <i>Apmis</i> , 2011, 119, 537-542.	0.9	9
92	A Novel Mechanism of High-Level, Broad-Spectrum Antibiotic Resistance Caused by a Single Base Pair Change in <i>Neisseria gonorrhoeae</i> . <i>MBio</i> , 2011, 2, .	1.8	77
93	Emergence, spread and characteristics of <i>Neisseria gonorrhoeae</i> isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden. <i>Sexually Transmitted Infections</i> , 2010, 86, 454-460.	0.8	80